Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ruud Doorn
Lenalidomide Combined With Low-Dose Cyclophosphamide and Prednisone Modulates Ikaros and Aiolos in Lymphocytes, Resulting in Immunostimulatory Effects in Lenalidomide-Refractory Multiple Myeloma Patients
Oncotarget
Oncology
Related publications
Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma
Hematology
Hematology
Lenalidomide−prednisone Induction Followed by Lenalidomide−melphalan−prednisone Consolidation and Lenalidomide−prednisone Maintenance in Newly Diagnosed Elderly Unfit Myeloma Patients
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Proteasome Inhibitors Block Ikaros Degradation by Lenalidomide in Multiple Myeloma
Haematologica
Hematology
Pembrolizumab Combined With Lenalidomide and Low‐dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE ‐023 Study
British Journal of Haematology
Hematology
Lenalidomide Induced Stroke in Multiple Myeloma
Clinical Practice
Medicine
Pharmacology
Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Update on the Role of Lenalidomide in Patients With Multiple Myeloma
Therapeutic Advances in Hematology
Hematology
Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
GRP-024 Antithrombotic Prophylaxis in Patients With Multiple Myeloma Being Treated With Lenalidomide
European Journal of Hospital Pharmacy: Science and Practice
Pharmacy
